Ken H Young
Professor of Pathology
I am a clinically-oriented diagnostic physician with clinical expertise in the pathologic diagnosis of hematologic cancers including tumors of the bone marrow, lymphoid tissue, spleen and pre-malignant hematologic conditions. Another area of interest is blood cancer classification with molecular and genetic profiling. In my research program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. In addition to patient care and translational research, medical education and scientific communication are also part of interest. I provide persistent support for the physician-scientist program and Blood Cancer Pathology program in the department and cancer center. Many residents, fellows, graduates and postdocs have worked and been trained in our program. We perform comprehensive clinical and research functions that include bone marrow, lymphoma pathology, clinical flow cytometry, cytogenetics, molecular diagnostics and outside services.
I am currently the director of hematopathology division that provides diagnostic consultation services and relevant specialized testing for patients with various types of acute and chronic leukemia, lymphoma and benign hematologic disorders. I am specialized in the diagnosis of hematological disorders, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, B and T-cell lymphomas, Hodgkin lymphoma, cutaneous and orbital lymphomas and benign bone marrow and lymph node disorders.
Our group has been supported by various funding resources since 2006 and has published 318 original peer-reviewed articles and 56 review articles, many in high- impact journals (Nature Clin Onc Rev, JCO, JAMA, Lancet, Blood, JHO, Leukemia and Clinical Cancer Research). The contributions to the hematology field include the development of novel diagnostic algorithms, molecular and genetic biomarkers for classification of blood cancer, lymphoid neoplasms and lymphoid diseases.
Current Research Interests
- Molecular and Genetic Profiling in Aggressive Lymphoma
- Pathologic and Molecular Classification of Lymphoma
- Biomarker study and Risk Stratification in Lymphoma
Office Hours
Division of Hematopathology and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, 40 Duke Medicine Circle, Room 265M, Box 3712, Duke South, Green Zone, Durham, NC 27710. Office Phone: 1-919-668-7568
Current Appointments & Affiliations
- Professor of Pathology, Pathology, Clinical Science Departments 2019
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2019
Contact Information
- 1-919-668-7568, 40 Medicine Circle, Durham, NC 27710
- 40 Duke Medicine Circle, Box #3712 Duhs, Durham, NC 27710
-
ken.young@duke.edu
(919) 668-7568
- Background
-
Education, Training, & Certifications
- Fellowship, Pathology, University of Nebraska Medical Center 2003 - 2005
- Residency, Pathology, Oregon Health and Science University 1999 - 2003
- Ph.D., Lund University (Sweden) 1995
- M.D., Zhejiang University (China) 1984
-
Medical Licensure
- NCMB2019. North Carolina. 2019
- TMB2010. Texas. 2010
-
Leadership & Clinical Positions at Duke
-
- Professor and Director, Hematopathology Division, Department of Pathology, Clinical Science Department, 2021 - Current
- Member and Chief of Blood Cancer Pathology Program, Duke Cancer Institute and Duke University Medical Center, 2019 - Current
- Professor with tenure, Department of Hematopathology, University of Texas MD Anderson Cancer Center, 2016-2019
- Associate Professor, Department of Hematopathology, University of Texas MD Anderson Cancer Center, 2010-2015
-
-
Academic Positions Outside Duke
- Professor with tenure, The University fo Texas MD Anderson Cancer Center. 2010 - 2019
- Expertise
-
Subject Headings
- Research
-
Selected Grants
- Hematology & Transfusion Medicine (T32) awarded by National Institutes of Health 1975 - 2026
- Role of SLAMF7 in Racial Disparities in t(11;14) myeloma awarded by National Cancer Institute 2023 - 2025
- Genetic and Epigenetic Biomarkers for B-cell Lymphoma awarded by National Institutes of Health 2020 - 2024
- Spatially resolved, single cell biomarkers of B cell lymphoma awarded by Cedars Sinai Medical Center 2022 - 2023
-
External Relationships
- Arima Genomics, CA
- Flagship Biosciences, CO
- Pregene Therapeutics
- Union Precision Medical Diagnostics
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Al-Juhaishi, Taha, Yingjun Wang, Denái R. Milton, Zijun Y. Xu-Monette, Elias Jabbour, May Daher, Jin S. Im, et al. “Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.” Bone Marrow Transplant, May 18, 2023. https://doi.org/10.1038/s41409-023-02006-3.Full Text Link to Item
-
Li, Yong, Zijun Y. Xu-Monette, Jeremy Abramson, Aliyah R. Sohani, Govind Bhagat, Alexandar Tzankov, Carlo Visco, et al. “EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.” Blood Adv 7, no. 7 (April 11, 2023): 1308–11. https://doi.org/10.1182/bloodadvances.2022008550.Full Text Link to Item
-
Pang, Yuyang, Tingxun Lu, Zijun Y. Xu-Monette, and Ken H. Young. “Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.” Int J Mol Sci 24, no. 6 (March 13, 2023). https://doi.org/10.3390/ijms24065493.Full Text Link to Item
-
Wang, Xinhua, Ken H. Young, and Mingzhi Zhang. “Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters-Reply.” Jama Oncol 9, no. 2 (February 1, 2023): 279–80. https://doi.org/10.1001/jamaoncol.2022.6463.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Haidan Liu, Xu Wang, Cristian Coarfa, Chao Cheng, Xinlian Yu, et al. “PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination.” J Clin Invest 133, no. 3 (February 1, 2023). https://doi.org/10.1172/JCI160456.Full Text Link to Item
-
Yu, Tiantian, Qing-Qing Cai, Qiong-Li Zhai, Ling Li, Xiaosheng Fang, Jianyong Li, Ruifang Sun, et al. “Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.” Leuk Lymphoma 63, no. 13 (December 2022): 3082–91. https://doi.org/10.1080/10428194.2022.2118528.Full Text Link to Item
-
Sang, Wei, Yuhan Ma, Xiangmin Wang, Yuanyuan Ma, Ziyuan Shen, Weiying Gu, Fei Wang, et al. “Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.” Am J Surg Pathol 46, no. 11 (November 1, 2022): 1533–44. https://doi.org/10.1097/PAS.0000000000001957.Full Text Open Access Copy Link to Item
-
Gisriel, Savanah D., Ji Yuan, Ryan C. Braunberger, Danielle L. V. Maracaja, Xueyan Chen, Xiaojun Wu, Jenna McCracken, et al. “Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.” Mod Pathol 35, no. 10 (October 2022): 1411–22. https://doi.org/10.1038/s41379-022-01091-x.Full Text Link to Item
-
Liu, Long, Xingxing Yu, Zhifeng Li, Xiaohua He, Jie Zha, Zhijuan Lin, Yan Hong, et al. “Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.” J Hematol Oncol 15, no. 1 (August 22, 2022): 115. https://doi.org/10.1186/s13045-022-01326-z.Full Text Link to Item
-
Luo, Cancan, Tiantian Yu, Ken H. Young, and Li Yu. “HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.” J Zhejiang Univ Sci B 23, no. 8 (August 15, 2022): 666–81. https://doi.org/10.1631/jzus.B2200016.Full Text Link to Item
-
Wang, Xinhua, Lei Zhang, Xiangli Liu, Xin Li, Ling Li, Xiaorui Fu, Zhenchang Sun, et al. “Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.” Jama Oncol 8, no. 7 (July 1, 2022): 1035–41. https://doi.org/10.1001/jamaoncol.2022.1968.Full Text Open Access Copy Link to Item
-
Wang, Xu, Xinfang Yu, Wei Li, Praveen Neeli, Ming Liu, Ling Li, Mingzhi Zhang, Xiaosheng Fang, Ken H. Young, and Yong Li. “Expanding anti-CD38 immunotherapy for lymphoid malignancies.” J Exp Clin Cancer Res 41, no. 1 (June 28, 2022): 210. https://doi.org/10.1186/s13046-022-02421-2.Full Text Open Access Copy Link to Item
-
Zhang, Shangkun, Chaojiang Gu, Lifang Huang, Han Wu, Jiangzhou Shi, Zijian Zhang, Yong Zhou, et al. “The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.” Sci Rep 12, no. 1 (June 21, 2022): 10488. https://doi.org/10.1038/s41598-022-14523-0.Full Text Open Access Copy Link to Item
-
Nie, Jiali, Li Yang, Liang Huang, Lili Gao, Ken He Young, Jehane Michael Le Grange, Xingcheng Yang, Jia Wei, Min Xiao, and Jianfeng Zhou. “Infection complications in febrile chimeric antigen receptor (CAR)-T recipients during the peri-CAR-T cell treatment period examined using metagenomic next-generation sequencing (mNGS).” Cancer Commun (Lond) 42, no. 5 (May 2022): 476–80. https://doi.org/10.1002/cac2.12260.Full Text Link to Item
-
Zhang, Wei, Qilin Ao, Yuqi Guan, Zhoujie Zhu, Dong Kuang, Monica M. Q. Li, Kefeng Shen, et al. “A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.” Mod Pathol 35, no. 5 (May 2022): 632–39. https://doi.org/10.1038/s41379-021-00954-z.Full Text Link to Item
-
Elfrink, Suraya, Martin Ter Beest, Luuk Janssen, Marijke P. Baltissen, Pascal W. T. C. Jansen, Angelique N. Kenyon, Raymond M. Steen, et al. “IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.” Blood Adv 6, no. 7 (April 12, 2022): 2254–66. https://doi.org/10.1182/bloodadvances.2021004366.Full Text Link to Item
-
Xu-Monette, Zijun Y., Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, et al. “Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.” Clin Cancer Res 28, no. 5 (March 1, 2022): 972–83. https://doi.org/10.1158/1078-0432.CCR-21-2949.Full Text Link to Item
-
Pandey, Poonam R., Ken H. Young, Dhiraj Kumar, and Neeraj Jain. “RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics.” Mol Cancer 21, no. 1 (February 21, 2022): 58. https://doi.org/10.1186/s12943-022-01528-6.Full Text Open Access Copy Link to Item
-
Albitar, Maher, Hong Zhang, Andre Goy, Zijun Y. Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, et al. “Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.” Blood Cancer J 12, no. 2 (February 1, 2022): 25. https://doi.org/10.1038/s41408-022-00617-5.Full Text Link to Item
-
Liu, Hui, Zijun Y. Xu-Monette, Guilin Tang, Wei Wang, Young Kim, Ji Yuan, Yu Li, et al. “EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.” Histopathology 80, no. 3 (February 2022): 575–88. https://doi.org/10.1111/his.14585.Full Text
-
Feng, Xiaomeng, Wei Guo, Yinping Wang, Jia Li, Yangzhi Zhao, Limei Qu, Xu Yan, et al. “The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.” Adv Ther 39, no. 1 (January 2022): 532–43. https://doi.org/10.1007/s12325-021-01943-z.Full Text Link to Item
-
Liu, Wanying, Qingqing Cai, Tiantian Yu, Paolo Strati, Frederick B. Hagemeister, Qiongli Zhai, Mingzhi Zhang, et al. “Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.” Am J Cancer Res 12, no. 9 (2022): 4227–40.Link to Item
-
Wan, Xin, Wei Guo, Xingtong Wang, Jia Li, Yangzhi Zhao, Xiaomeng Feng, Ken H. Young, and Ou Bai. “Improving the prognostic ability of PET/CT SUVmax to identify follicular lymphoma with early treatment failure.” American Journal of Cancer Research 12, no. 8 (January 2022): 3857–69.
-
Yu, Fang, Hua He, Loretta J. Nastoupil, Zijun Y. Xu-Monette, Ky Pham, Yong Liang, Guang Chen, et al. “Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma.” Am J Cancer Res 12, no. 10 (2022): 4666–79.Link to Item
-
Martinez-Baquero, Diana, Ali Sakhdari, Huan Mo, Do Hwan Kim, Rashmi Kanagal-Shamanna, Shaoying Li, Ken H. Young, et al. “EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.” Mod Pathol 34, no. 12 (December 2021): 2183–91. https://doi.org/10.1038/s41379-021-00885-9.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Ken H. Young, and Yong Li. “Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave.” Biomedicines 9, no. 11 (November 16, 2021). https://doi.org/10.3390/biomedicines9111702.Full Text Link to Item
-
Youssef, Youssef, Vrajesh Karkhanis, Wing Keung Chan, Frankie Jeney, Alessandro Canella, Xiaoli Zhang, Shelby Sloan, et al. “Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.” Haematologica 106, no. 11 (November 1, 2021): 2927–39. https://doi.org/10.3324/haematol.2020.268235.Full Text Link to Item
-
Tian, Xiao-Peng, Shu-Yun Ma, Ken H. Young, Choon Kiat Ong, Yan-Hui Liu, Zhi-Hua Li, Qiong-Li Zhai, et al. “A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma.” Blood 138, no. 6 (August 12, 2021): 452–63. https://doi.org/10.1182/blood.2020010637.Full Text Link to Item
-
Lei, Wen, Mixue Xie, Qi Jiang, Nengwen Xu, Ping Li, Aibin Liang, Ken H. Young, and Wenbin Qian. “Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.” Cancers (Basel) 13, no. 15 (August 3, 2021). https://doi.org/10.3390/cancers13153912.Full Text Open Access Copy Link to Item
-
Chen, Pu, Lucas Redd, Yao Schmidt, Prasad Koduru, Franklin Fuda, Crystal Montgomery-Goecker, Kirthi Kumar, et al. “MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.” Leuk Res 106 (July 2021): 106584. https://doi.org/10.1016/j.leukres.2021.106584.Full Text Link to Item
-
Cheng, Wei, Tian-Tian Yu, Ai-Ping Tang, Ken He Young, and Li Yu. “Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.” Curr Med Sci 41, no. 3 (June 2021): 405–19. https://doi.org/10.1007/s11596-021-2393-3.Full Text Link to Item
-
Fang, Xiaosheng, and Ken H. Young. “Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.” Leuk Lymphoma 62, no. 6 (June 2021): 1281–83. https://doi.org/10.1080/10428194.2021.1891233.Full Text Link to Item
-
Morse, Daniel C., Katherine E. Park, Vida Chitsazzadeh, Shaoying Li, Ken Young, Jillian R. Gunther, Bouthaina S. Dabaja, and Madeleine Duvic. “Vulvar Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma.” Int J Gynecol Pathol 40, no. 3 (May 1, 2021): 229–33. https://doi.org/10.1097/PGP.0000000000000648.Full Text Link to Item
-
Wang, Yingjun, Vasantha Lakshmi Gali, Zijun Y. Xu-Monette, Dahlia Sano, Sheeba K. Thomas, Donna M. Weber, Feng Zhu, et al. “Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.” Neoplasia 23, no. 4 (April 2021): 361–74. https://doi.org/10.1016/j.neo.2021.02.002.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Qipan Deng, Haidan Liu, Xu Wang, Hui Hu, Ya Cao, et al. “MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.” Blood 137, no. 12 (March 25, 2021): 1615–27. https://doi.org/10.1182/blood.2020004918.Full Text Link to Item
-
Young, Ken H. “Intensive chemotherapy and sequential hematopoietic stem cell transplantation: Is it necessary for high-risk T-cell lymphoblastic lymphoma?” Cancer Commun (Lond) 41, no. 3 (March 2021): 273–74. https://doi.org/10.1002/cac2.12148.Full Text Link to Item
-
Liang, Yun, Hui Liu, Zheming Lu, Wen Lei, Chaoting Zhang, Ping Li, Aibin Liang, Ken H. Young, and Wenbin Qian. “CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.” J Hematol Oncol 14, no. 1 (February 16, 2021): 26. https://doi.org/10.1186/s13045-021-01044-y.Full Text Link to Item
-
Deng, Manman, Zijun Y. Xu-Monette, Lan V. Pham, Xudong Wang, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, et al. “Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.” Mol Cancer Res 19, no. 2 (February 2021): 249–60. https://doi.org/10.1158/1541-7786.MCR-20-0466.Full Text Link to Item
-
Bao, Changqian, Xiandong Tao, Wei Cui, Yuanyuan Hao, Shuaike Zheng, Bin Yi, Tiewen Pan, Ken H. Young, and Wenbin Qian. “Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients.” Exp Hematol Oncol 10, no. 1 (January 27, 2021): 5. https://doi.org/10.1186/s40164-021-00199-1.Full Text Link to Item
-
Liu, Hui, Wen Lei, Chaoting Zhang, Chunmei Yang, Juying Wei, Qunyi Guo, Xiaojun Guo, et al. “CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.” Clin Cancer Res 27, no. 2 (January 15, 2021): 473–84. https://doi.org/10.1158/1078-0432.CCR-20-1457.Full Text Link to Item
-
Yuan, Delin, Genhong Li, Lian Yu, Yuelong Jiang, Yuanfei Shi, Qiulin Chen, Xiaomei Ma, et al. “CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements.” Front Oncol 11 (2021): 618908. https://doi.org/10.3389/fonc.2021.618908.Full Text Open Access Copy Link to Item
-
Fang, Xiaosheng, Zhongling Sun, Zijun Y. Xu-Monette, and Ken H. Young. “Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions.” The Oncologist 26, no. 1 (January 2021): 4–6. https://doi.org/10.1002/onco.13605.Full Text
-
You, Hua, Zijun Y. Xu-Monette, Li Wei, Harry Nunns, Máté L. Nagy, Govind Bhagat, Xiaosheng Fang, et al. “Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.” Oncoimmunology 10, no. 1 (2021): 1928365. https://doi.org/10.1080/2162402X.2021.1928365.Full Text Link to Item
-
Zhou, Shan, Chunmei Fan, Zhaoyang Zeng, Ken H. Young, and Yong Li. “Clinical and Immunological Effects of p53-Targeting Vaccines.” Front Cell Dev Biol 9 (2021): 762796. https://doi.org/10.3389/fcell.2021.762796.Full Text Link to Item
-
Wang, Liang, Lin-Rong Li, and Ken H. Young. “New agents and regimens for diffuse large B cell lymphoma.” J Hematol Oncol 13, no. 1 (December 14, 2020): 175. https://doi.org/10.1186/s13045-020-01011-z.Full Text Link to Item
-
Lyapichev, Kirill A., Ali Sakhdari, Joseph D. Khoury, Dennis P. O’Malley, Siba El Hussein, Cameron C. Yin, Keyur P. Patel, et al. “Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma.” Ann Diagn Pathol 49 (December 2020): 151636. https://doi.org/10.1016/j.anndiagpath.2020.151636.Full Text Link to Item
-
Xu-Monette, Zijun Y., and Ken H. Young. “Therapeutic vaccines for aggressive B-cell lymphoma.” Leuk Lymphoma 61, no. 13 (December 2020): 3038–51. https://doi.org/10.1080/10428194.2020.1805113.Full Text Link to Item
-
Deng, Manman, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, et al. “XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.” J Hematol Oncol 13, no. 1 (November 4, 2020): 148. https://doi.org/10.1186/s13045-020-00982-3.Full Text Link to Item
-
Young, Ken H. “Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.” Leukemia 34, no. 11 (November 2020): 3075–76. https://doi.org/10.1038/s41375-020-0861-6.Full Text Link to Item
-
Yang, Chunmei, Mixue Xie, Kaifeng Zhang, Hui Liu, Aibin Liang, Ken H. Young, and Wenbin Qian. “Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.” Leukemia 34, no. 11 (November 2020): 3055–59. https://doi.org/10.1038/s41375-020-0913-y.Full Text
-
Yu, Li, Menghan Shi, Qingqing Cai, Paolo Strati, Fredrick Hagemeister, Qiongli Zhai, Ling Li, et al. “A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.” Oncologist 25, no. 11 (November 2020): 963–73. https://doi.org/10.1634/theoncologist.2019-0986.Full Text Link to Item
-
Chen, Kai, Qianying Yang, Jie Zha, Manman Deng, Yong Zhou, Guofeng Fu, Silei Bi, et al. “Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia.” Cell Death Dis 11, no. 9 (September 18, 2020): 778. https://doi.org/10.1038/s41419-020-02972-2.Full Text Link to Item
-
Huang, Xinxing, Ken H. Young, Wei Guo, Yinping Wang, Xueju Wang, Yanfeng Xi, Lifen Wang, and Ou Bai. “Identification of hepatitis B virus aetiologic antigens, HBx and Pre-S2, in diffuse large B-cell lymphoma.” Journal of Viral Hepatitis 27, no. 9 (September 2020): 948–50. https://doi.org/10.1111/jvh.13301.Full Text
-
Liu, Ming, Xu Wang, Wei Li, Xinfang Yu, Pedro Flores-Villanueva, Zijun Y. Xu-Monette, Ling Li, et al. “Targeting PD-L1 in non-small cell lung cancer using CAR T cells.” Oncogenesis 9, no. 8 (August 13, 2020): 72. https://doi.org/10.1038/s41389-020-00257-z.Full Text Link to Item
-
Xu-Monette, Zijun Y., Hongwei Zhang, Feng Zhu, Alexandar Tzankov, Govind Bhagat, Carlo Visco, Karen Dybkaer, et al. “A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.” Blood Adv 4, no. 14 (July 28, 2020): 3391–3404. https://doi.org/10.1182/bloodadvances.2020001949.Full Text Link to Item
-
Soderquist, Craig R., Nupam Patel, Vundavalli V. Murty, Shane Betman, Nidhi Aggarwal, Ken H. Young, Luc Xerri, et al. “Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.” Haematologica 105, no. 7 (July 2020): 1895–1906. https://doi.org/10.3324/haematol.2019.230961.Full Text Link to Item
-
Zhang, Wei, Li Yang, Yu’ Qi Guan, Ke’ Feng Shen, Mei’ Lan Zhang, Hao’ Dong Cai, Jia’ Chen Wang, et al. “Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.” Bmc Cancer 20, no. 1 (July 2020): 714. https://doi.org/10.1186/s12885-020-07198-1.Full Text
-
Sobhani, Navid, Alberto D’Angelo, Xu Wang, Ken H. Young, Daniele Generali, and Yong Li. “Mutant p53 as an Antigen in Cancer Immunotherapy.” Int J Mol Sci 21, no. 11 (June 8, 2020). https://doi.org/10.3390/ijms21114087.Full Text Link to Item
-
Zhou, Hui, Zijun Y. Xu-Monette, Ling Xiao, Paolo Strati, Fredrick B. Hagemeister, Yizi He, Huan Chen, et al. “Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.” Blood Cancer J 10, no. 5 (May 4, 2020): 49. https://doi.org/10.1038/s41408-020-0312-7.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Haidan Liu, Qipan Deng, Xu Wang, Hui Hu, Zijun Y. Xu-Monette, et al. “Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation.” J Hematol Oncol 13, no. 1 (May 1, 2020): 40. https://doi.org/10.1186/s13045-020-00869-3.Full Text Link to Item
-
Keane, Colm, Soi C. Law, Clare Gould, Simone Birch, Muhammed B. Sabdia, Lilia Merida de Long, Gayathri Thillaiyampalam, et al. “LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.” Blood Adv 4, no. 7 (April 14, 2020): 1367–77. https://doi.org/10.1182/bloodadvances.2019001390.Full Text Link to Item
-
Young, Ken H. “Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?” Leukemia 34, no. 4 (April 2020): 1213–14. https://doi.org/10.1038/s41375-019-0608-4.Full Text Link to Item
-
Due, Hanne, Rasmus Froberg Brøndum, Ken H. Young, Martin Bøgsted, and Karen Dybkær. “MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.” Bmc Cancer 20, no. 1 (March 20, 2020): 237. https://doi.org/10.1186/s12885-020-6643-8.Full Text Link to Item
-
Li, Zhaoming, Yue Song, Yanjie Zhang, Chaoping Li, Yingjun Wang, Weili Xue, Lisha Lu, et al. “Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma.” Haematologica 105, no. 3 (March 2020): e107–10. https://doi.org/10.3324/haematol.2019.220863.Full Text Link to Item
-
Lyapichev, Kirill A., Sergio Piña-Oviedo, L Jeffrey Medeiros, Mark G. Evans, Hui Liu, Alonso R. Miranda, Kelly K. Hunt, et al. “A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.” Mod Pathol 33, no. 3 (March 2020): 367–79. https://doi.org/10.1038/s41379-019-0337-2.Full Text Link to Item
-
You, Liangshun, Qingqing Lin, Jing Zhao, Fangjing Shi, Ken H. Young, and Wenbin Qian. “Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease.” Br J Haematol 188, no. 5 (March 2020): e64–67. https://doi.org/10.1111/bjh.16330.Full Text Link to Item
-
Shi, Ke, Qian Sun, Chun Qiao, Huayuan Zhu, Li Wang, Jiazhu Wu, Lili Wang, et al. “98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.” Cancer Med 9, no. 3 (February 2020): 999–1007. https://doi.org/10.1002/cam4.2788.Full Text Link to Item
-
Bao, Changqian, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H. Young, and Wenbin Qian. “SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients.” Exp Hematol Oncol 9 (2020): 16. https://doi.org/10.1186/s40164-020-00172-4.Full Text Link to Item
-
Gallardo, Miguel, Prerna Malaney, Marisa J. L. Aitken, Xiaorui Zhang, Todd M. Link, Vrutant Shah, Sanzhar Alybayev, et al. “Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.” J Natl Cancer Inst 112, no. 1 (January 1, 2020): 95–106. https://doi.org/10.1093/jnci/djz078.Full Text Link to Item
-
Cascione, Luciano, Andrea Rinaldi, Alessio Bruscaggin, Chiara Tarantelli, Alberto J. Arribas, Ivo Kwee, Lorenza Pecciarini, et al. “Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.” Haematologica 104, no. 12 (December 2019): e558–61. https://doi.org/10.3324/haematol.2018.214957.Full Text Link to Item
-
Deng, Qipan, Hui Hu, Xinfang Yu, Shuanglin Liu, Lei Wang, Weiqun Chen, Chi Zhang, et al. “Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.” Nat Commun 10, no. 1 (November 7, 2019): 5061. https://doi.org/10.1038/s41467-019-13002-x.Full Text Link to Item
-
Xu-Monette, Zijun Y., Jianyong Li, Yi Xia, Beryl Crossley, Robert D. Bremel, Yi Miao, Min Xiao, et al. “Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.” J Immunother Cancer 7, no. 1 (October 22, 2019): 272. https://doi.org/10.1186/s40425-019-0730-x.Full Text Link to Item
-
Kim, Do Hwan, L Jeffrey Medeiros, Phyu P. Aung, Ken H. Young, Roberto N. Miranda, and Chi Young Ok. “Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.” Am J Surg Pathol 43, no. 10 (October 2019): 1421–28. https://doi.org/10.1097/PAS.0000000000001312.Full Text Link to Item
-
Miao, Yi, L Jeffrey Medeiros, Yong Li, Jianyong Li, and Ken H. Young. “Genetic alterations and their clinical implications in DLBCL.” Nat Rev Clin Oncol 16, no. 10 (October 2019): 634–52. https://doi.org/10.1038/s41571-019-0225-1.Full Text Open Access Copy Link to Item
-
Li, Zhaoming, Xudong Zhang, Weili Xue, Yanjie Zhang, Chaoping Li, Yue Song, Mei Mei, et al. “Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.” Nat Commun 10, no. 1 (September 16, 2019): 4209. https://doi.org/10.1038/s41467-019-12032-9.Full Text Link to Item
-
Yu, Li, Tian-Tian Yu, and Ken H. Young. “Cross-talk between Myc and p53 in B-cell lymphomas.” Chronic Dis Transl Med 5, no. 3 (September 2019): 139–54. https://doi.org/10.1016/j.cdtm.2019.08.001.Full Text Link to Item
-
Kazma, J., C. Johnson, N. Jain, V. L. Gali, K. H. Young, and A. A. Jazaeri. “B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature.” Gynecologic Oncology Reports 29 (August 1, 2019): 94–97. https://doi.org/10.1016/j.gore.2019.08.003.Full Text
-
Wang, Lei, Qipan Deng, Hui Hu, Ming Liu, Zhaojian Gong, Shanshan Zhang, Zijun Y. Xu-Monette, et al. “Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.” J Hematol Oncol 12, no. 1 (July 5, 2019): 70. https://doi.org/10.1186/s13045-019-0767-9.Full Text Link to Item
-
Chamoun, Kamal, Denái R. Milton, Celina Ledesma, Ken H. Young, Elias J. Jabbour, Gheath Alatrash, Paolo Anderlini, et al. “Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.” Biol Blood Marrow Transplant 25, no. 7 (July 2019): 1347–54. https://doi.org/10.1016/j.bbmt.2019.02.022.Full Text Link to Item
-
Li, Lin-Rong, Liang Wang, Ying-Zhi He, and Ken H. Young. “Current perspectives on the treatment of double hit lymphoma.” Expert Rev Hematol 12, no. 7 (July 2019): 507–14. https://doi.org/10.1080/17474086.2019.1623020.Full Text Link to Item
-
Li, Ling, Ruifang Sun, Yi Miao, Thai Tran, Lisa Adams, Nathan Roscoe, Bing Xu, et al. “PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.” Mod Pathol 32, no. 6 (June 2019): 741–54. https://doi.org/10.1038/s41379-018-0193-5.Full Text Open Access Copy Link to Item
-
Liu, Huan, Jin He, Su Pin Koh, Yuping Zhong, Zhiqiang Liu, Zhiqiang Wang, Yujin Zhang, et al. “Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.” Sci Transl Med 11, no. 494 (May 29, 2019). https://doi.org/10.1126/scitranslmed.aau9087.Full Text Link to Item
-
Due, Hanne, Anna Amanda Schönherz, Laura Ryø, Maria Nascimento Primo, Ditte Starberg Jespersen, Emil Aagaard Thomsen, Anne Stidholt Roug, et al. “MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.” Blood Adv 3, no. 7 (April 9, 2019): 1185–96. https://doi.org/10.1182/bloodadvances.2018029660.Full Text Link to Item
-
Li, Zhaoming, Xuan Lan, Chaoping Li, Yanjie Zhang, Yingjun Wang, Weili Xue, Lisha Lu, et al. “Recurrent PDGFRB mutations in unicentric Castleman disease.” Leukemia 33, no. 4 (April 2019): 1035–38. https://doi.org/10.1038/s41375-018-0323-6.Full Text Link to Item
-
Xu-Monette, Ziju Y., Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, et al. “Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.” Cancer Immunol Res 7, no. 4 (April 2019): 644–57. https://doi.org/10.1158/2326-6066.CIR-18-0439.Full Text Link to Item
-
Cai, Q., Y. Fang, and K. H. Young. “Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.” Translational Oncology 12, no. 3 (March 1, 2019): 523–38. https://doi.org/10.1016/j.tranon.2018.11.011.Full Text
-
Cai, Q., J. Cai, Y. Fang, and K. H. Young. “Epstein-Barr virus-positive natural killer/T-cell lymphoma.” Frontiers in Oncology 9, no. MAY (January 1, 2019). https://doi.org/10.3389/fonc.2019.00386.Full Text
-
Miao, Yi, L Jeffrey Medeiros, Zijun Y. Xu-Monette, Jianyong Li, and Ken H. Young. “Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.” Front Oncol 9 (2019): 107. https://doi.org/10.3389/fonc.2019.00107.Full Text Open Access Copy Link to Item
-
Li, Li, Jun Zhang, Juan Chen, Zijun Y. Xu-Monette, Yi Miao, Min Xiao, Ken H. Young, et al. “B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.” Blood 132, no. 17 (October 25, 2018): 1805–17. https://doi.org/10.1182/blood-2018-03-841015.Full Text Link to Item
-
Zhang, J., L. J. Medeiros, and K. H. Young. “Cancer immunotherapy in diffuse large B-cell lymphoma.” Frontiers in Oncology 8, no. SEP (September 10, 2018). https://doi.org/10.3389/fonc.2018.00351.Full Text
-
Pham, Lan V., Shengjian Huang, Hui Zhang, Jun Zhang, Taylor Bell, Shouhao Zhou, Elizabeth Pogue, et al. “Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.” Clin Cancer Res 24, no. 16 (August 15, 2018): 3967–80. https://doi.org/10.1158/1078-0432.CCR-17-3004.Full Text Link to Item
-
Alatrash, Gheath, Alexander A. Perakis, Celine Kerros, Haley L. Peters, Pariya Sukhumalchandra, Mao Zhang, Haroon Jakher, et al. “Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.” Clin Cancer Res 24, no. 14 (July 15, 2018): 3386–96. https://doi.org/10.1158/1078-0432.CCR-17-2626.Full Text Link to Item
-
Huang, Qian, Jiajia Xi, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, et al. “Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.” J Hematol Oncol 11, no. 1 (July 3, 2018): 90. https://doi.org/10.1186/s13045-018-0633-1.Full Text Link to Item
-
Castillo, Jorge J., Brady E. Beltran, Roberto N. Miranda, Ken H. Young, Julio C. Chavez, and Eduardo M. Sotomayor. “EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.” Am J Hematol 93, no. 7 (July 2018): 953–62. https://doi.org/10.1002/ajh.25112.Full Text Link to Item
-
Miao, Y., L. J. Medeiros, J. Li, and K. H. Young. “Diffuse large B-cell lymphoma with molecular variations more than ABC and GCB classification.” Precision Cancer Medicine 1, no. July (July 1, 2018). https://doi.org/10.21037/pcm.2018.06.03.Full Text
-
Wang, Xiaoxiao, Xin Cao, Ruifang Sun, Charlene Tang, Alexandar Tzankov, Jun Zhang, Ganiraju C. Manyam, et al. “Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.” Neoplasia 20, no. 6 (June 2018): 574–93. https://doi.org/10.1016/j.neo.2018.03.002.Full Text Link to Item
-
Xi, Jiajia, Qian Huang, Lei Wang, Xiaodong Ma, Qipan Deng, Munish Kumar, Zhiyuan Zhou, et al. “miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.” Oncogene 37, no. 23 (June 2018): 3151–65. https://doi.org/10.1038/s41388-018-0178-3.Full Text Link to Item
-
Chahoud, Jad, Dawen Sui, William D. Erwin, Alison M. Gulbis, Martin Korbling, Mingzhi Zhang, Sairah Ahmed, et al. “Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.” Clin Cancer Res 24, no. 10 (May 15, 2018): 2304–11. https://doi.org/10.1158/1078-0432.CCR-17-3561.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Qipan Deng, Ling Li, Eric D. Hsi, Ken H. Young, Mingzhi Zhang, and Yong Li. “MYD88 L265P Mutation in Lymphoid Malignancies.” Cancer Res 78, no. 10 (May 15, 2018): 2457–62. https://doi.org/10.1158/0008-5472.CAN-18-0215.Full Text Link to Item
-
García-Barchino, Maria J., Maria E. Sarasquete, Carlos Panizo, Julie Morscio, Antonio Martinez, Miguel Alcoceba, Vicente Fresquet, et al. “Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.” J Pathol 245, no. 1 (May 2018): 61–73. https://doi.org/10.1002/path.5060.Full Text Link to Item
-
Huang, Qian, Jiajia Xia, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, et al. “miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.” J Hematol Oncol 11, no. 1 (April 23, 2018): 58. https://doi.org/10.1186/s13045-018-0600-x.Full Text Link to Item
-
Quesada, Andrés E., Ken H. Young, L Jeffrey Medeiros, and Beenu Thakral. “Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease.” Pathology 50, no. 3 (April 2018): 351–52. https://doi.org/10.1016/j.pathol.2017.09.017.Full Text Link to Item
-
Li, Ling, Sa Xiao, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, et al. “An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.” Oncotarget 9, no. 22 (March 23, 2018): 16213–19. https://doi.org/10.18632/oncotarget.23806.Full Text Link to Item
-
Ferrufino-Schmidt, Maria C., L Jeffrey Medeiros, Hui Liu, Mark W. Clemens, Kelly K. Hunt, Camille Laurent, Julian Lofts, et al. “Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma.” Am J Surg Pathol 42, no. 3 (March 2018): 293–305. https://doi.org/10.1097/PAS.0000000000000985.Full Text Link to Item
-
Jain, N., H. Zhu, T. Khashab, Q. Ye, B. George, R. Mathur, R. K. Singh, et al. “Targeting nucleolin for better survival in diffuse large B-cell lymphoma.” Leukemia 32, no. 3 (March 2018): 663–74. https://doi.org/10.1038/leu.2017.215.Full Text Link to Item
-
Sun, R. F., Q. Q. Yu, and K. H. Young. “Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.” Chronic Diseases and Translational Medicine 4, no. 1 (March 1, 2018): 29–44. https://doi.org/10.1016/j.cdtm.2018.02.001.Full Text
-
Hu, Zhihong, Yi Sun, Ellen J. Schlette, Guilin Tang, Shaoying Li, Jie Xu, C Cameron Yin, et al. “CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.” Mod Pathol 31, no. 2 (February 2018): 327–36. https://doi.org/10.1038/modpathol.2017.135.Full Text Link to Item
-
Yao, Z., L. Deng, Z. Y. Xu-Monette, G. C. Manyam, P. Jain, A. Tzankov, C. Visco, et al. “Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.” Leukemia 32, no. 2 (February 2018): 353–63. https://doi.org/10.1038/leu.2017.222.Full Text Link to Item
-
Li, Xin, Yasong Cheng, Mingzhi Zhang, Jiaqin Yan, Ling Li, Xiaorui Fu, Xudong Zhang, et al. “Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.” J Hematol Oncol 11, no. 1 (January 31, 2018): 15. https://doi.org/10.1186/s13045-018-0559-7.Full Text Link to Item
-
Xu-Monette, Zijun Y., Jianfeng Zhou, and Ken H. Young. “PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.” Blood 131, no. 1 (January 4, 2018): 68–83. https://doi.org/10.1182/blood-2017-07-740993.Full Text Open Access Copy Link to Item
-
Liu, Wei, Juan Chen, Archito T. Tamayo, Changgeng Ruan, Li Li, Shouhao Zhou, Chan Shen, et al. “Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.” Oncotarget 9, no. 1 (January 2, 2018): 346–60. https://doi.org/10.18632/oncotarget.20378.Full Text Link to Item
-
Li, Shaoying, Ken H. Young, and L Jeffrey Medeiros. “Diffuse large B-cell lymphoma.” Pathology 50, no. 1 (January 2018): 74–87. https://doi.org/10.1016/j.pathol.2017.09.006.Full Text Link to Item
-
Wu, Huanling, L Jeffrey Medeiros, and Ken H. Young. “Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.” Blood Rev 32, no. 1 (January 2018): 8–28. https://doi.org/10.1016/j.blre.2017.08.004.Full Text Open Access Copy Link to Item
-
Ho, Jennifer C., Bouthaina S. Dabaja, Sarah A. Milgrom, Grace L. Smith, Jay P. Reddy, Ali Mazloom, Ken H. Young, et al. “Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.” Leuk Lymphoma 58, no. 12 (December 2017): 2833–44. https://doi.org/10.1080/10428194.2017.1312381.Full Text Link to Item
-
Visco, Carlo, Jinfen Wang, Maria Chiara Tisi, Lijuan Deng, Emanuele S. G. D’Amore, Alexandar Tzankov, Santiago Montes-Moreno, et al. “Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.” Br J Cancer 117, no. 11 (November 21, 2017): 1685–88. https://doi.org/10.1038/bjc.2017.345.Full Text Link to Item
-
Li, Xin, Zijun Y. Xu-Monette, Shuhua Yi, Bouthaina S. Dabaja, Ganiraju C. Manyam, Jason Westin, Nathan Fowler, et al. “Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.” Am J Surg Pathol 41, no. 10 (October 2017): 1309–21. https://doi.org/10.1097/PAS.0000000000000923.Full Text Link to Item
-
Li, Ling, Wenjing Duan, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, et al. “The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.” Br J Haematol 178, no. 5 (September 2017): 772–80. https://doi.org/10.1111/bjh.14763.Full Text Link to Item
-
Wang, Jinfen, Zijun Y. Xu-Monette, Kausar J. Jabbar, Qi Shen, Ganiraju C. Manyam, Alexandar Tzankov, Carlo Visco, et al. “AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.” Am J Pathol 187, no. 8 (August 2017): 1700–1716. https://doi.org/10.1016/j.ajpath.2017.04.009.Full Text Link to Item
-
Atsaves, V., N. Tsesmetzis, D. Chioureas, L. Kis, V. Leventaki, E. Drakos, T. Panaretakis, et al. “PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.” Leukemia 31, no. 7 (July 2017): 1633–37. https://doi.org/10.1038/leu.2017.103.Full Text Link to Item
-
Cai, Qingqing, Meifeng Tu, Zijun Y. Xu-Monette, Ruifang Sun, Ganiraju C. Manyam, Xiaolu Xu, Alexander Tzankov, et al. “NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.” Mod Pathol 30, no. 6 (June 2017): 854–76. https://doi.org/10.1038/modpathol.2017.5.Full Text Link to Item
-
Ok, Chi Young, and Ken H. Young. “Checkpoint inhibitors in hematological malignancies.” J Hematol Oncol 10, no. 1 (May 8, 2017): 103. https://doi.org/10.1186/s13045-017-0474-3.Full Text Link to Item
-
Montalban-Bravo, Guillermo, Christopher B. Benton, Sa A. Wang, Farhad Ravandi, Tapan Kadia, Jorge Cortes, Naval Daver, et al. “More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.” Blood 129, no. 18 (May 4, 2017): 2584–87. https://doi.org/10.1182/blood-2016-11-749903.Full Text Link to Item
-
Agbay, Rose Lou Marie C., Carlos A. Torres-Cabala, Keyur P. Patel, Eric D. Merril, Madeleine Duvic, Andres Quesada, Victor G. Prieto, et al. “Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.” Am J Surg Pathol 41, no. 4 (April 2017): 431–45. https://doi.org/10.1097/PAS.0000000000000786.Full Text Link to Item
-
Yu, Li, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, et al. “Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.” Blood 129, no. 12 (March 23, 2017): 1658–68. https://doi.org/10.1182/blood-2016-11-748855.Full Text Open Access Copy Link to Item
-
Liu, Zhiyu, L Jeffrey Medeiros, and Ken H. Young. “Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis.” Hematol Oncol 35, no. 1 (March 2017): 125–29. https://doi.org/10.1002/hon.2203.Full Text Link to Item
-
Ok, Chi Young, and Ken H. Young. “Targeting the programmed death-1 pathway in lymphoid neoplasms.” Cancer Treat Rev 54 (March 2017): 99–109. https://doi.org/10.1016/j.ctrv.2017.01.009.Full Text Link to Item
-
Xia, Y., Z. Y. Xu-Monette, A. Tzankov, X. Li, G. C. Manyam, V. Murty, G. Bhagat, et al. “Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.” Leukemia 31, no. 3 (March 2017): 625–36. https://doi.org/10.1038/leu.2016.243.Full Text Open Access Copy Link to Item
-
Yu, Li, Ling Li, L Jeffrey Medeiros, and Ken H. Young. “NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.” Blood Rev 31, no. 2 (March 2017): 77–92. https://doi.org/10.1016/j.blre.2016.10.001.Full Text Link to Item
-
Hu, Zhihong, L Jeffrey Medeiros, Zi Chen, Weina Chen, Shaoying Li, Sergej N. Konoplev, Xinyan Lu, et al. “Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.” Am J Surg Pathol 41, no. 2 (February 2017): 216–24. https://doi.org/10.1097/PAS.0000000000000758.Full Text Link to Item
-
Yabe, Mariko, L Jeffrey Medeiros, Yahya Daneshbod, Masoud Davanlou, Carlos E. Bueso-Ramos, Elisa J. Moran, Ken H. Young, and Roberto N. Miranda. “Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.” Ann Diagn Pathol 26 (February 2017): 16–22. https://doi.org/10.1016/j.anndiagpath.2016.10.005.Full Text Link to Item
-
Sun, Ruifang, Jinfen Wang, and Ken H. Young. “Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.” Crit Rev Oncog 22, no. 5–6 (2017): 527–57. https://doi.org/10.1615/CritRevOncog.2017020816.Full Text Link to Item
-
Xu-Monette, Zijun Y., Mingzhi Zhang, Jianyong Li, and Ken H. Young. “PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?” Front Immunol 8 (2017): 1597. https://doi.org/10.3389/fimmu.2017.01597.Full Text Link to Item
-
Yabe, Mariko, L Jeffrey Medeiros, Sa A. Wang, Guilin Tang, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Govind Bhagat, et al. “Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis.” Am J Surg Pathol 41, no. 1 (January 2017): 82–93. https://doi.org/10.1097/PAS.0000000000000743.Full Text Link to Item
-
Xu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand, et al. “Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.” Blood 128, no. 26 (December 29, 2016): 3083–3100. https://doi.org/10.1182/blood-2016-05-715094.Full Text Link to Item
-
Xu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand, et al. “Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.” Blood 128, no. 26 (December 29, 2016): 3083–3100. https://doi.org/10.1182/blood-2016-05715094.Full Text Open Access Copy Link to Item
-
Mai, Yun, J Jessica Yu, Boris Bartholdy, Zijun Y. Xu-Monette, Esther E. Knapp, Fei Yuan, Hongshan Chen, et al. “An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.” Blood 128, no. 24 (December 15, 2016): 2797–2807. https://doi.org/10.1182/blood-2016-03-705814.Full Text Link to Item
-
Zhang, Mingzhi, Zijun Y. Xu-Monette, Ling Li, Ganiraju C. Manyam, Carlo Visco, Alexandar Tzankov, Jing Wang, et al. “RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.” Aging (Albany Ny) 8, no. 12 (December 8, 2016): 3321–40. https://doi.org/10.18632/aging.101121.Full Text Link to Item
-
Pham, Lan V., Jerry L. Bryant, Richard Mendez, Juan Chen, Archito T. Tamayo, Zijun Y. Xu-Monette, Ken H. Young, et al. “Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.” Oncotarget 7, no. 49 (December 6, 2016): 80599–611. https://doi.org/10.18632/oncotarget.12413.Full Text Link to Item
-
Loghavi, Sanam, Sa A. Wang, L Jeffrey Medeiros, Jeffrey L. Jorgensen, Xin Li, Zijun Y. Xu-Monette, Roberto N. Miranda, and Ken H. Young. “Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.” Leuk Lymphoma 57, no. 12 (December 2016): 2804–12. https://doi.org/10.3109/10428194.2016.1170827.Full Text Link to Item
-
Yi, S., D. Zou, and K. H. Young. “Decipher the 2016 revision of the World Health Organization classification of lymphoid neoplasms.” National Medical Journal of China 96, no. 42 (November 15, 2016): 3365–69. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.42.002.Full Text
-
Sun, Ruifang, L Jeffrey Medeiros, and Ken H. Young. “Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.” Mod Pathol 29, no. 10 (October 2016): 1118–42. https://doi.org/10.1038/modpathol.2016.92.Full Text Link to Item
-
Zhang, Lei, Sisi Jia, Yangyang Ma, Ling Li, Xin Li, Xinhua Wang, Xiaorui Fu, et al. “Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.” Oncotarget 7, no. 34 (August 23, 2016): 55721–31. https://doi.org/10.18632/oncotarget.10124.Full Text Link to Item
-
Tang, Z., L. J. Medeiros, C. C. Yin, W. Wang, X. Lu, K. H. Young, J. D. Khoury, and G. Tang. “Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: A diagnostic dilemma for clinical cytogeneticists.” Molecular Cytogenetics 9, no. 1 (August 8, 2016). https://doi.org/10.1186/s13039-016-0275-3.Full Text
-
Xu-Monette, Zijun Y., Qipan Deng, Ganiraju C. Manyam, Alexander Tzankov, Ling Li, Yi Xia, Xiao-Xiao Wang, et al. “Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 22, no. 14 (July 2016): 3593–3605. https://doi.org/10.1158/1078-0432.ccr-15-2296.Full Text
-
Cao, Xin, L Jeffrey Medeiros, Yi Xia, Xiaoxiao Wang, Sheeba K. Thomas, Sanam Loghavi, Xin Li, et al. “Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.” Leuk Lymphoma 57, no. 5 (May 2016): 1104–13. https://doi.org/10.3109/10428194.2015.1096357.Full Text Link to Item
-
Castillo, Jorge J., Brady E. Beltran, Roberto N. Miranda, Ken H. Young, Julio C. Chavez, and Eduardo M. Sotomayor. “EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.” Am J Hematol 91, no. 5 (May 2016): 529–37. https://doi.org/10.1002/ajh.24370.Full Text Link to Item
-
Xia, Yi, L Jeffrey Medeiros, and Ken H. Young. “Immune checkpoint blockade: Releasing the brake towards hematological malignancies.” Blood Rev 30, no. 3 (May 2016): 189–200. https://doi.org/10.1016/j.blre.2015.11.003.Full Text Link to Item
-
Yabe, Mariko, L Jeffrey Medeiros, Guilin Tang, Sa A. Wang, Sairah Ahmed, Yago Nieto, Shimin Hu, et al. “Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.” Am J Surg Pathol 40, no. 5 (May 2016): 676–88. https://doi.org/10.1097/PAS.0000000000000614.Full Text Link to Item
-
Wu, Wei, Huayuan Zhu, Yuan Fu, Wenyi Shen, Kourong Miao, Min Hong, Wei Xu, et al. “High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid.” Oncotarget 7, no. 16 (April 19, 2016): 21631–43. https://doi.org/10.18632/oncotarget.7795.Full Text Link to Item
-
Batlle-López, Ana, Sonia González de Villambrosía, Mazorra Francisco, Sefora Malatxeberria, Anabel Sáez, Carlos Montalban, Lydia Sánchez, et al. “Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.” Oncotarget 7, no. 14 (April 5, 2016): 18036–49. https://doi.org/10.18632/oncotarget.7495.Full Text Link to Item
-
Aye, Le Le, Sanam Loghavi, Ken H. Young, Imran Siddiqi, C Cameron Yin, Mark J. Routbort, Mei Liang, et al. “Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases.” Ann Diagn Pathol 21 (April 2016): 53–58. https://doi.org/10.1016/j.anndiagpath.2015.12.004.Full Text Link to Item
-
Yabe, Mariko, L Jeffrey Medeiros, Guilin Tang, Sa A. Wang, Keyur P Patel, Mark Routbort, Govind Bhagat, et al. “Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.” Hum Pathol 50 (April 2016): 109–17. https://doi.org/10.1016/j.humpath.2015.11.010.Full Text Link to Item
-
Kanagal-Shamanna, Rashmi, Zijun Y. Xu-Monette, Roberto N. Miranda, Ahmet Dogan, Dehui Zou, Rajyalakshmi Luthra, Donna M. Weber, et al. “Crystal-storing histiocytosis: a clinicopathological study of 13 cases.” Histopathology 68, no. 4 (March 2016): 482–91. https://doi.org/10.1111/his.12768.Full Text Link to Item
-
Deng, L., Z. Y. Xu-Monette, S. Loghavi, G. C. Manyam, Y. Xia, C. Visco, J. Huh, et al. “Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.” Leukemia 30, no. 2 (February 2016): 361–72. https://doi.org/10.1038/leu.2015.237.Full Text Link to Item
-
Winde, Charlotte M. de, Sharon Veenbergen, Ken H. Young, Zijun Y. Xu-Monette, Xiao-Xiao Wang, Yi Xia, Kausar J. Jabbar, et al. “Tetraspanin CD37 protects against the development of B cell lymphoma.” J Clin Invest 126, no. 2 (February 2016): 653–66. https://doi.org/10.1172/JCI81041.Full Text Link to Item
-
Xu-Monette, Zijun Y., Shanxiang Zhang, Xin Li, Ganiraju C. Manyam, Xiao-Xiao Wang, Yi Xia, Carlo Visco, et al. “p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.” Aging (Albany Ny) 8, no. 2 (February 2016): 345–65. https://doi.org/10.18632/aging.100898.Full Text Link to Item
-
Borges, Natália M., Marcela do Vale Elias, Veruska L. Fook-Alves, Tathiana A. Andrade, Marina Lourenço de Conti, Mariana Petaccia Macedo, Maria Dirlei Begnami, et al. “Angiomirs expression profiling in diffuse large B-Cell lymphoma.” Oncotarget 7, no. 4 (January 26, 2016): 4806–16. https://doi.org/10.18632/oncotarget.6624.Full Text Link to Item
-
Ye, Qing, Zijun Y. Xu-Monette, Alexandar Tzankov, Lijuan Deng, Xiaoxiao Wang, Ganiraju C. Manyam, Carlo Visco, et al. “Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.” Oncotarget 7, no. 3 (January 19, 2016): 2401–16. https://doi.org/10.18632/oncotarget.6262.Full Text Link to Item
-
Clemens, Mark W., L Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Steven Horwitz, Dennis D. Weisenburger, et al. “Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.” J Clin Oncol 34, no. 2 (January 10, 2016): 160–68. https://doi.org/10.1200/JCO.2015.63.3412.Full Text Link to Item
-
Falgreen, Steffen, Anders Ellern Bilgrau, Rasmus Froberg Brøndum, Lasse Hjort Jakobsen, Jonas Have, Kasper Lindblad Nielsen, Tarec Christoffer El-Galaly, et al. “hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.” Plos One 11, no. 10 (2016): e0163711. https://doi.org/10.1371/journal.pone.0163711.Full Text Link to Item
-
Lu, Ting-Xun, Ken H. Young, Wei Xu, and Jian-Yong Li. “TP53 dysfunction in diffuse large B-cell lymphoma.” Crit Rev Oncol Hematol 97 (January 2016): 47–55. https://doi.org/10.1016/j.critrevonc.2015.08.006.Full Text Link to Item
-
Tang, Z., G. Tang, S. A. Wang, X. Lu, K. H. Young, C. E. Bueso-Ramos, Y. Alvarado, L. J. Medeiros, and J. D. Khoury. “Simultaneous deletion of 3'ETV6 and 5' EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: Case report and literature review.” Molecular Cytogenetics 9, no. 1 (January 1, 2016). https://doi.org/10.1186/s13039-016-0232-1.Full Text
-
Wang, Michael L., Hun Lee, Hubert Chuang, Nicolaus Wagner-Bartak, Frederick Hagemeister, Jason Westin, Luis Fayad, et al. “Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.” Lancet Oncol 17, no. 1 (January 2016): 48–56. https://doi.org/10.1016/S1470-2045(15)00438-6.Full Text Link to Item
-
Xia, Yi, L. Jeffrey Medeiros, and Ken H. Young. “Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.” Biochim Biophys Acta 1865, no. 1 (January 2016): 58–71. https://doi.org/10.1016/j.bbcan.2015.09.002.Full Text Link to Item
-
Wang, Xiaoxiao, Huiqiang Huang, and Ken H. Young. “The PTEN tumor suppressor gene and its role in lymphoma pathogenesis.” Aging (Albany Ny) 7, no. 12 (December 2015): 1032–49. https://doi.org/10.18632/aging.100855.Full Text Link to Item
-
Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Xiaoxiao Wang, Meifeng Tu, Ganiraju C. Manyam, Alexander Tzankov, Yi Xia, et al. “Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.” Mod Pathol 28, no. 12 (December 2015): 1555–73. https://doi.org/10.1038/modpathol.2015.118.Full Text Link to Item
-
Cai, Qingqing, L Jeffrey Medeiros, Xiaolu Xu, and Ken H. Young. “MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.” Oncotarget 6, no. 36 (November 17, 2015): 38591–616. https://doi.org/10.18632/oncotarget.5774.Full Text Link to Item
-
Gordon, Michael W., Fang Yan, Xiaoming Zhong, Pranab Behari Mazumder, Zijun Y. Xu-Monette, Dehui Zou, Ken H. Young, Kenneth S. Ramos, and Yong Li. “Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma.” Molecular Carcinogenesis 54, no. 10 (October 2015): 1060–69. https://doi.org/10.1002/mc.22175.Full Text
-
Liu, Zhiyu, Zijun Y. Xu-Monette, Xin Cao, Ganiraju C. Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, et al. “Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.” Mod Pathol 28, no. 10 (October 2015): 1297–1314. https://doi.org/10.1038/modpathol.2015.94.Full Text Link to Item
-
Yabe, Mariko, L Jeffrey Medeiros, Sa A. Wang, Sergej Konoplev, Chi Young Ok, Sanam Loghavi, Gary Lu, et al. “Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With αβ T-Cell Large Granular Lymphocytic Leukemia. [corrected].” Am J Clin Pathol 144, no. 4 (October 2015): 607–19. https://doi.org/10.1309/AJCPJSA1E1YWSZEY.Full Text Link to Item
-
Deng, Lijuan, Yuqin Song, Ken H. Young, Shimin Hu, Ning Ding, Weiwei Song, Xianghong Li, et al. “Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.” Oncotarget 6, no. 28 (September 22, 2015): 25061–73. https://doi.org/10.18632/oncotarget.4677.Full Text Link to Item
-
Li, Ling, Zijun Y. Xu-Monette, Chi Young Ok, Alexandar Tzankov, Ganiraju C. Manyam, Ruifang Sun, Carlo Visco, et al. “Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.” Oncotarget 6, no. 27 (September 15, 2015): 23157–80. https://doi.org/10.18632/oncotarget.4319.Full Text Link to Item
-
Brauner, S., W. Zhou, C. Backlin, T. M. Green, L. Folkersen, M. Ivanchenko, B. Löfström, et al. “Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.” J Intern Med 278, no. 3 (September 2015): 323–32. https://doi.org/10.1111/joim.12375.Full Text Link to Item
-
Hatanpaa, Kimmo J., Franklin Fuda, Prasad Koduru, Ken Young, Bradley Lega, and Weina Chen. “Lymphomatosis Cerebri: A Diagnostic Challenge.” Jama Neurol 72, no. 9 (September 2015): 1066–67. https://doi.org/10.1001/jamaneurol.2015.1149.Full Text Link to Item
-
Ok, Chi Young, Zijun Y. Xu-Monette, Ling Li, Ganiraju C. Manyam, Santiago Montes-Moreno, Alexandar Tzankov, Carlo Visco, et al. “Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.” Mod Pathol 28, no. 9 (September 2015): 1202–13. https://doi.org/10.1038/modpathol.2015.76.Full Text Link to Item
-
Wang, Wei, Shimin Hu, Xinyan Lu, Ken H. Young, and L Jeffrey Medeiros. “Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.” Am J Surg Pathol 39, no. 8 (August 2015): 1132–39. https://doi.org/10.1097/PAS.0000000000000434.Full Text Link to Item
-
Lu, Ting-Xun, Lei Fan, Li Wang, Jia-Zhu Wu, Kou-Rong Miao, Jin-Hua Liang, Qi-Xing Gong, et al. “MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.” Oncotarget 6, no. 21 (July 30, 2015): 18374–88. https://doi.org/10.18632/oncotarget.4073.Full Text Link to Item
-
Visco, Carlo, Erika Falisi, Ken H. Young, Michela Pascarella, Omar Perbellini, Giuseppe Carli, Elisabetta Novella, et al. “Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.” Oncotarget 6, no. 21 (July 30, 2015): 18653–63. https://doi.org/10.18632/oncotarget.4418.Full Text Link to Item
-
Ok, Chi Young, and Ken H. Young. “Age cutoff in lymphoma diagnosis.” Aging (Albany Ny) 7, no. 7 (July 2015): 451–52. https://doi.org/10.18632/aging.100774.Full Text Link to Item
-
Cao, Xin, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, et al. “Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.” J Hematol Oncol 8 (June 24, 2015): 74. https://doi.org/10.1186/s13045-015-0172-y.Full Text Link to Item
-
Ok, Chi Young, Qing Ye, Ling Li, Ganiraju C. Manyam, Lijuan Deng, Rashmi R. Goswami, Xiaoxiao Wang, et al. “Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?” Oncotarget 6, no. 16 (June 10, 2015): 13933–45. https://doi.org/10.18632/oncotarget.4324.Full Text Link to Item
-
Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carlo Visco, Lalitha Nagarajan, et al. “Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.” Oncotarget 6, no. 16 (June 10, 2015): 14720. https://doi.org/10.18632/oncotarget.4464.Full Text Link to Item
-
Li, Yu, Shimin Hu, Zhuang Zuo, Ming Hong, Pei Lin, Shaoying Li, Sergej Konoplev, et al. “CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.” Mod Pathol 28, no. 6 (June 2015): 787–98. https://doi.org/10.1038/modpathol.2015.42.Full Text Link to Item
-
Testoni, M., E. Zucca, K. H. Young, and F. Bertoni. “Genetic lesions in diffuse large B-cell lymphomas.” Ann Oncol 26, no. 6 (June 2015): 1069–80. https://doi.org/10.1093/annonc/mdv019.Full Text Link to Item
-
Ok, Chi Young, Keyur P. Patel, Guillermo Garcia-Manero, Mark J. Routbort, Jie Peng, Guilin Tang, Maitrayee Goswami, et al. “TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.” J Hematol Oncol 8 (May 8, 2015): 45. https://doi.org/10.1186/s13045-015-0139-z.Full Text Link to Item
-
Ma, Xiaodong, Daniel J. Conklin, Fenge Li, Zhongping Dai, Xiang Hua, Yan Li, Zijun Y. Xu-Monette, et al. “The oncogenic microRNA miR-21 promotes regulated necrosis in mice.” Nature Communications 6 (May 2015): 7151. https://doi.org/10.1038/ncomms8151.Full Text
-
Dybkær, Karen, Martin Bøgsted, Steffen Falgreen, Julie S. Bødker, Malene K. Kjeldsen, Alexander Schmitz, Anders E. Bilgrau, et al. “Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.” J Clin Oncol 33, no. 12 (April 20, 2015): 1379–88. https://doi.org/10.1200/JCO.2014.57.7080.Full Text Link to Item
-
Falgreen, Steffen, Karen Dybkær, Ken H. Young, Zijun Y. Xu-Monette, Tarec C. El-Galaly, Maria Bach Laursen, Julie S. Bødker, et al. “Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.” Bmc Cancer 15 (April 8, 2015): 235. https://doi.org/10.1186/s12885-015-1237-6.Full Text Link to Item
-
Chen, Jiayu, Zijun Y. Xu-Monette, Lijuan Deng, Qi Shen, Ganiraju C. Manyam, Azahara Martinez-Lopez, Li Zhang, et al. “Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.” Oncotarget 6, no. 8 (March 20, 2015): 5597–5614. https://doi.org/10.18632/oncotarget.3343.Full Text Link to Item
-
Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carol Visco, Lalitha Nagarajan, et al. “Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.” Oncotarget 6, no. 8 (March 20, 2015): 5615–33. https://doi.org/10.18632/oncotarget.3479.Full Text Link to Item
-
Ok, Chi Young, Keyur P. Patel, Guillermo Garcia-Manero, Mark J. Routbort, Bin Fu, Guilin Tang, Maitrayee Goswami, et al. “Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.” Leuk Res 39, no. 3 (March 2015): 348–54. https://doi.org/10.1016/j.leukres.2014.12.006.Full Text Link to Item
-
Zhang, Li-Na, Li Wang, Cheng Fang, Zhi-Jian Zou, Lei Fan, Run Zhang, Ken H. Young, Jian-Yong Li, and Wei Xu. “The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma.” Leuk Lymphoma 56, no. 3 (March 2015): 676–81. https://doi.org/10.3109/10428194.2014.927455.Full Text Link to Item
-
Cai, Qingqing, Kailin Chen, and Ken H. Young. “Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.” Exp Mol Med 47, no. 1 (January 23, 2015): e133. https://doi.org/10.1038/emm.2014.105.Full Text Link to Item
-
Ok, Chi Young, Ling Li, and Ken H. Young. “EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.” Exp Mol Med 47, no. 1 (January 23, 2015): e132. https://doi.org/10.1038/emm.2014.82.Full Text Link to Item
-
Cui, Yingying, Xin Li, Zhenchang Sun, Changsen Leng, Ken Young, Xiaolong Wu, Lei Zhang, et al. “Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma.” Leuk Lymphoma 56, no. 9 (2015): 2613–18. https://doi.org/10.3109/10428194.2015.1014366.Full Text Link to Item
-
Andrade, Tathiana Azevedo de, Adriane Feijo Evangelista, Antonio Hugo Froes Campos, Wagner Augusto Poles, Natalia Morais Borges, Claudia Malheiros Coutinho Camillo, Fernando Augusto Soares, et al. “A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.” Oncotarget 5, no. 23 (December 15, 2014): 11813–26. https://doi.org/10.18632/oncotarget.2952.Full Text Link to Item
-
Liu, Ju, C. Zhang, X. L. Wang, P. Ly, V. Belyi, Z. Y. Xu-Monette, K. H. Young, W. Hu, and Z. Feng. “E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.” Cell Death Differ 21, no. 11 (November 2014): 1792–1804. https://doi.org/10.1038/cdd.2014.121.Full Text Link to Item
-
Yu, Haiyang, Xuetian Yue, Yuhan Zhao, Xiaoyan Li, Lihua Wu, Cen Zhang, Zhen Liu, et al. “LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.” Nat Commun 5 (October 17, 2014): 5218. https://doi.org/10.1038/ncomms6218.Full Text Link to Item
-
Odqvist, Lina, Santiago Montes-Moreno, Roxana E. Sánchez-Pacheco, Ken H. Young, Esperanza Martín-Sánchez, Laura Cereceda, Lydia Sánchez-Verde, et al. “NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.” Mod Pathol 27, no. 10 (October 2014): 1331–37. https://doi.org/10.1038/modpathol.2014.34.Full Text Link to Item
-
Ok, Chi Young, Jiayu Chen, Zijun Y. Xu-Monette, Alexandar Tzankov, Ganiraju C. Manyam, Ling Li, Carlo Visco, et al. “Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.” Clin Cancer Res 20, no. 19 (October 1, 2014): 5113–23. https://doi.org/10.1158/1078-0432.CCR-14-0683.Full Text Link to Item
-
Cai, Qingqing, Xiaolin Luo, Guanrong Zhang, Huiqiang Huang, Hui Huang, Tongyu Lin, Wenqi Jiang, Zhongjun Xia, and Ken H. Young. “New prognostic model for extranodal natural killer/T cell lymphoma, nasal type.” Ann Hematol 93, no. 9 (September 2014): 1541–49. https://doi.org/10.1007/s00277-014-2089-x.Full Text Link to Item
-
Adrada, Beatriz E., Roberto N. Miranda, Gaiane Margishvili Rauch, Elsa Arribas, Rashmi Kanagal-Shamanna, Mark W. Clemens, Michelle Fanale, et al. “Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients.” Breast Cancer Res Treat 147, no. 1 (August 2014): 1–14. https://doi.org/10.1007/s10549-014-3034-3.Full Text Link to Item
-
Chang, Yuan-I, Alisa Damnernsawad, Laura K. Allen, David Yang, Erik A. Ranheim, Ken H. Young, Jingfang Zhang, et al. “Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.” Br J Haematol 166, no. 3 (August 2014): 461–65. https://doi.org/10.1111/bjh.12871.Full Text Link to Item
-
Wang, Shi, L Jeffrey Medeiros, Zijun Y. Xu-Monette, Shanxiang Zhang, Dennis P. O’Malley, Attilio Orazi, Zhuang Zuo, et al. “Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.” Ann Diagn Pathol 18, no. 4 (August 2014): 203–9. https://doi.org/10.1016/j.anndiagpath.2014.03.007.Full Text Link to Item
-
Tzankov, Alexandar, Zijun Y. Xu-Monette, Marc Gerhard, Carlo Visco, Stephan Dirnhofer, Nora Gisin, Karen Dybkaer, et al. “Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.” Mod Pathol 27, no. 7 (July 2014): 958–71. https://doi.org/10.1038/modpathol.2013.214.Full Text Link to Item
-
Ok, Chi Young, Zijun Y. Xu-Monette, Alexandar Tzankov, Dennis P. O’Malley, Santiago Montes-Moreno, Carlo Visco, Michael B. Møller, et al. “Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Cancer 120, no. 12 (June 15, 2014): 1818–29. https://doi.org/10.1002/cncr.28664.Full Text Link to Item
-
Deng, Qipan, Lindsey Becker, Xiaodong Ma, Xiaoming Zhong, Ken Young, Kenneth Ramos, and Yong Li. “The dichotomy of p53 regulation by noncoding RNAs.” J Mol Cell Biol 6, no. 3 (June 2014): 198–205. https://doi.org/10.1093/jmcb/mju017.Full Text Link to Item
-
Kong, Guangyao, Mark Wunderlich, David Yang, Erik A. Ranheim, Ken H. Young, Jinyong Wang, Yuan-I Chang, et al. “Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.” J Clin Invest 124, no. 6 (June 2014): 2762–73. https://doi.org/10.1172/JCI74182.Full Text Link to Item
-
Liu, Juan, Cen Zhang, Meihua Lin, Wei Zhu, Yingjian Liang, Xuehui Hong, Yuhan Zhao, Ken H. Young, Wenwei Hu, and Zhaohui Feng. “Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.” Oncotarget 5, no. 9 (May 15, 2014): 2635–47. https://doi.org/10.18632/oncotarget.1862.Full Text Link to Item
-
Ok, Chi Young, Ling Li, Zijun Y. Xu-Monette, Carlo Visco, Alexander Tzankov, Ganiraju C. Manyam, Santiago Montes-Moreno, et al. “Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.” Clin Cancer Res 20, no. 9 (May 1, 2014): 2338–49. https://doi.org/10.1158/1078-0432.CCR-13-3157.Full Text Link to Item
-
Wang, Sa A., Robert P. Hasserjian, Patricia S. Fox, Heesun J. Rogers, Julia T. Geyer, Devon Chabot-Richards, Elizabeth Weinzierl, et al. “Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.” Blood 123, no. 17 (April 24, 2014): 2645–51. https://doi.org/10.1182/blood-2014-02-553800.Full Text Link to Item
-
Sotomayor, Eduardo M., Ken H. Young, and Anas Younes. “Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.” Clin Adv Hematol Oncol 12, no. 4 Suppl 10 (April 2014): 1–22.Link to Item
-
Young, K. H. “CD30 diagnostics and testing.” Clinical Advances in Hematology and Oncology 12, no. 4 (April 1, 2014): 9–15.
-
Zheng, Wenli, L Jeffrey Medeiros, Ken H. Young, Maitrayee Goswami, Linda Powers, Hagop H. Kantarjian, Deborah A. Thomas, Jorge E. Cortes, and Sa A. Wang. “CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis.” Leuk Lymphoma 55, no. 3 (March 2014): 624–27. https://doi.org/10.3109/10428194.2013.820293.Full Text Link to Item
-
Zhu, Huayuan, Wei Wu, Yuan Fu, Wenyi Shen, Kourong Miao, Min Hong, Wei Xu, Ken H. Young, Peng Liu, and Jianyong Li. “Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia.” Ann Hematol 93, no. 3 (March 2014): 425–35. https://doi.org/10.1007/s00277-013-1883-1.Full Text Link to Item
-
Miranda, Roberto N., Tariq N. Aladily, H Miles Prince, Rashmi Kanagal-Shamanna, Daphne de Jong, Luis E. Fayad, Mitual B. Amin, et al. “Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.” J Clin Oncol 32, no. 2 (January 10, 2014): 114–20. https://doi.org/10.1200/JCO.2013.52.7911.Full Text Link to Item
-
Han, L., F. Liu, R. Li, Z. Li, X. Chen, Z. Zhou, X. Zhang, et al. “Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.” Oncology Letters 8, no. 4 (January 1, 2014): 1461–69. https://doi.org/10.3892/ol.2014.2356.Full Text
-
Han, L., M. Zhang, L. Li, L. Zhang, J. Wu, X. Li, X. Wang, et al. “Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report.” Oncology Letters 8, no. 2 (January 1, 2014): 886–90. https://doi.org/10.3892/ol.2014.2202.Full Text
-
Jain, Preetesh, and Ken H. Young. “Haematological cancer: Richter's transformation in CLL-a distinct lymphoma.” Nat Rev Clin Oncol 11, no. 1 (January 2014): 6–8. https://doi.org/10.1038/nrclinonc.2013.229.Full Text Link to Item
-
Ok, C. Y., R. P. Hasserjian, P. S. Fox, F. Stingo, Z. Zuo, K. H. Young, K. Patel, L. J. Medeiros, G. Garcia-Manero, and S. A. Wang. “Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.” Leukemia 28, no. 1 (January 2014): 185–89. https://doi.org/10.1038/leu.2013.191.Full Text Link to Item
-
Wang, Shi, Alexander Tzankov, Zijun Y. Xu-Monette, Sylvia Hoeller, Sa A. Wang, Kristy L. Richards, Shanxiang Zhang, Jonathan W. Said, L Jeffrey Medeiros, and Ken H. Young. “Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.” Hum Pathol 44, no. 12 (December 2013): 2658–67. https://doi.org/10.1016/j.humpath.2013.07.007.Full Text Link to Item
-
Frei, E., C. Visco, Z. Y. Xu-Monette, S. Dirnhofer, K. Dybkær, A. Orazi, G. Bhagat, et al. “Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.” J Clin Pathol 66, no. 11 (November 2013): 956–61. https://doi.org/10.1136/jclinpath-2013-201619.Full Text Link to Item
-
Boi, Michela, Andrea Rinaldi, Ivo Kwee, Paola Bonetti, Maria Todaro, Fabrizio Tabbò, Roberto Piva, et al. “PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.” Blood 122, no. 15 (October 10, 2013): 2683–93. https://doi.org/10.1182/blood-2013-04-497933.Full Text Link to Item
-
Chigrinova, Ekaterina, Andrea Rinaldi, Ivo Kwee, Davide Rossi, Paola M. V. Rancoita, Jonathan C. Strefford, David Oscier, et al. “Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.” Blood 122, no. 15 (October 10, 2013): 2673–82. https://doi.org/10.1182/blood-2013-03-489518.Full Text Link to Item
-
Xu-Monette, Zijun Y., Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C. Manyam, Louise Kristensen, et al. “MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Blood 122, no. 15 (October 10, 2013): 2630–40. https://doi.org/10.1182/blood-2012-12-473702.Full Text Open Access Copy Link to Item
-
Jain, Preetesh, Xiuning Le, Ken H. Young, Keyur P. Patel, Sa Wang, Lin Pei, Lynne L. Barron, Lynne Abruzzo, and Susan O’Brien. “Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.” Clin Lymphoma Myeloma Leuk 13, no. 5 (October 2013): 606–9. https://doi.org/10.1016/j.clml.2013.04.007.Full Text Link to Item
-
Chou, Feng-Pai, Ya-Wen Chen, Xianfeng F. Zhao, Zijun Y. Xu-Monette, Ken H. Young, Ronald B. Gartenhaus, Jehng-Kang Wang, et al. “Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.” The American Journal of Pathology 183, no. 4 (October 2013): 1306–17. https://doi.org/10.1016/j.ajpath.2013.06.024.Full Text
-
Jain, Preetesh, Luis E. Fayad, Andreas Rosenwald, Ken H. Young, and Susan O’Brien. “Recent advances in de novo CD5+ diffuse large B cell lymphoma.” Am J Hematol 88, no. 9 (September 2013): 798–802. https://doi.org/10.1002/ajh.23467.Full Text Link to Item
-
Li, Shaoying, Pei Lin, Ken H. Young, Rashmi Kanagal-Shamanna, C Cameron Yin, and L Jeffrey Medeiros. “MYC/BCL2 double-hit high-grade B-cell lymphoma.” Adv Anat Pathol 20, no. 5 (September 2013): 315–26. https://doi.org/10.1097/PAP.0b013e3182a289f2.Full Text Link to Item
-
Wang, M., N. Fowler, N. Wagner-Bartak, L. Feng, J. Romaguera, S. S. Neelapu, F. Hagemeister, et al. “Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.” Leukemia 27, no. 9 (September 2013): 1902–9. https://doi.org/10.1038/leu.2013.95.Full Text Link to Item
-
Loo, Eric Y., L Jeffrey Medeiros, Tariq N. Aladily, Daniela Hoehn, Rashmi Kanagal-Shamanna, Ken H. Young, Pei Lin, et al. “Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases.” Am J Surg Pathol 37, no. 8 (August 2013): 1290–97. https://doi.org/10.1097/PAS.0b013e31828e6564.Full Text Link to Item
-
Rinaldi, Andrea, Ivo Kwee, Ken H. Young, Emanuele Zucca, Gianluca Gaidano, Francesco Forconi, and Francesco Bertoni. “Genome-wide high resolution DNA profiling of hairy cell leukaemia.” Br J Haematol 162, no. 4 (August 2013): 566–69. https://doi.org/10.1111/bjh.12393.Full Text Link to Item
-
Ok, Chi Young, Thomas G. Papathomas, L Jeffrey Medeiros, and Ken H. Young. “EBV-positive diffuse large B-cell lymphoma of the elderly.” Blood 122, no. 3 (July 18, 2013): 328–40. https://doi.org/10.1182/blood-2013-03-489708.Full Text Link to Item
-
Li, Yong, Michael W. Gordon, Zijun Y. Xu-Monette, Carlo Visco, Alexander Tzankov, Dehui Zou, Lugui Qiu, et al. “Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Blood 121, no. 22 (May 30, 2013): 4529–40. https://doi.org/10.1182/blood-2012-12-471722.Full Text Link to Item
-
Hu, Shimin, Zijun Y. Xu-Monette, Alexander Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, et al. “MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.” Blood 121, no. 20 (May 16, 2013): 4021–31. https://doi.org/10.1182/blood-2012-10-460063.Full Text Open Access Copy Link to Item
-
Hu, Shimin, Zijun Y. Xu-Monette, Aarthi Balasubramanyam, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Wei-min Liu, et al. “CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 121, no. 14 (April 4, 2013): 2715–24. https://doi.org/10.1182/blood-2012-10-461848.Full Text Open Access Copy Link to Item
-
Visco, Carlo, Alexander Tzankov, Zijun Y. Xu-Monette, Roberto N. Miranda, Yu Chuan Tai, Yan Li, Wei-min Liu, et al. “Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.” Haematologica 98, no. 2 (February 2013): 255–63. https://doi.org/10.3324/haematol.2012.066209.Full Text Link to Item
-
Hoeller, Sylvia, Yi Zhou, Rashmi Kanagal-Shamanna, Zijun Y. Xu-Monette, Daniela Hoehn, Michel Bihl, Steven H. Swerdlow, et al. “Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.” Hum Pathol 44, no. 1 (January 2013): 110–21. https://doi.org/10.1016/j.humpath.2012.04.022.Full Text Link to Item
-
Xu-Monette, Zijun Y., Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, et al. “Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 120, no. 19 (November 8, 2012): 3986–96. https://doi.org/10.1182/blood-2012-05-433334.Full Text Open Access Copy Link to Item
-
Hu, Shimin, Ken H. Young, Sergej N. Konoplev, and L Jeffrey Medeiros. “Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas.” Hum Pathol 43, no. 11 (November 2012): 1789–98. https://doi.org/10.1016/j.humpath.2012.05.002.Full Text Link to Item
-
Kanagal-Shamanna, Rashmi, L Jeffrey Medeiros, Gary Lu, Sa A. Wang, John T. Manning, Pei Lin, Gerald M. Penn, et al. “High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.” Histopathology 61, no. 5 (November 2012): 945–54. https://doi.org/10.1111/j.1365-2559.2012.04301.x.Full Text Link to Item
-
Green, Tina Marie, Ken H. Young, Carlo Visco, Zijun Y. Xu-Monette, Attilio Orazi, Ronald S. Go, Ole Nielsen, et al. “Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.” J Clin Oncol 30, no. 28 (October 1, 2012): 3460–67. https://doi.org/10.1200/JCO.2011.41.4342.Full Text Open Access Copy Link to Item
-
Takwi, Apana A. L., Yan Li, Lindsey E. Becker Buscaglia, Jingwen Zhang, Saibyasachi Choudhury, Ae Kyung Park, Mofang Liu, et al. “A statin-regulated microRNA represses human c-Myc expression and function.” Embo Mol Med 4, no. 9 (September 2012): 896–909. https://doi.org/10.1002/emmm.201101045.Full Text Link to Item
-
Visco, C., Y. Li, Z. Y. Xu-Monette, R. N. Miranda, T. M. Green, A. Tzankov, W. Wen, et al. “Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Leukemia 26, no. 9 (September 2012): 2103–13. https://doi.org/10.1038/leu.2012.83.Full Text Open Access Copy Link to Item
-
Aladily, Tariq N., L Jeffrey Medeiros, Mitual B. Amin, Nisreen Haideri, Dongjiu Ye, Sergio J. Azevedo, Jeffrey L. Jorgensen, et al. “Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases.” Am J Surg Pathol 36, no. 7 (July 2012): 1000–1008. https://doi.org/10.1097/PAS.0b013e31825749b1.Full Text Link to Item
-
Montes-Moreno, Santiago, Lina Odqvist, Julio A. Diaz-Perez, Ana Batlle Lopez, Sonia Gonzalez de Villambrosía, Francisco Mazorra, Maria E. Castillo, et al. “EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation.” Mod Pathol 25, no. 7 (July 2012): 968–82. https://doi.org/10.1038/modpathol.2012.52.Full Text Link to Item
-
Wang, Michael, Luis Fayad, Nicolaus Wagner-Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, et al. “Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.” Lancet Oncol 13, no. 7 (July 2012): 716–23. https://doi.org/10.1016/S1470-2045(12)70200-0.Full Text Link to Item
-
Xu-Monette, Zijun Y., and Ken H. Young. “The TP53 tumor suppressor and autophagy in malignant lymphoma.” Autophagy 8, no. 5 (May 2012): 842–45. https://doi.org/10.4161/auto.19703.Full Text
-
Green, Tina Marie, Ole Nielsen, Karin de Stricker, Zijun Y. Xu-Monette, Ken H. Young, and Michael Boe Møller. “High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.” Am J Surg Pathol 36, no. 4 (April 2012): 612–19. https://doi.org/10.1097/PAS.0b013e318244e2ba.Full Text Link to Item
-
Xu-Monette, Zijun Y., L Jeffrey Medeiros, Yong Li, Robert Z. Orlowski, Michael Andreeff, Carlos E. Bueso-Ramos, Timothy C. Greiner, Timothy J. McDonnell, and Ken H. Young. “Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.” Blood 119, no. 16 (April 2012): 3668–83. https://doi.org/10.1182/blood-2011-11-366062.Full Text
-
Papathomas, T. G., I. Venizelos, C. H. Dunphy, J. W. Said, M. L. Wang, E. Campo, S. H. Swerdlow, et al. “Mantle cell lymphoma as a component of composite lymphoma: Clinicopathologic parameters and biologic implications.” Human Pathology 43, no. 4 (January 1, 2012): 467–80. https://doi.org/10.1016/j.humpath.2011.08.024.Full Text
-
Zhou, Y., M. J. You, K. H. Young, P. Lin, G. Lu, L. J. Medeiros, and C. E. Bueso-Ramos. “Advances in the molecular pathobiology of B-lymphoblastic leukemia.” Human Pathology 43, no. 9 (January 1, 2012): 1347–62. https://doi.org/10.1016/j.humpath.2012.02.004.Full Text
-
Zhang, Jiang, Moltu J. Guy, Holly S. Norman, Yi-Chen Chen, Qingge Xu, Xintong Dong, Huseyin Guner, et al. “Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure.” J Proteome Res 10, no. 9 (September 2, 2011): 4054–65. https://doi.org/10.1021/pr200258m.Full Text Link to Item
-
Montes-Moreno, Santiago, Nerea Martinez, Beatriz Sanchez-Espiridión, Ramon Díaz Uriarte, Maria Elena Rodriguez, Anabel Saez, Carlos Montalbán, et al. “miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.” Blood 118, no. 4 (July 28, 2011): 1034–40. https://doi.org/10.1182/blood-2010-11-321554.Full Text Link to Item
-
Wang, Jinyong, Yangang Liu, Zeyang Li, Zhongde Wang, Li Xuan Tan, Myung-Jeom Ryu, Benjamin Meline, et al. “Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.” Blood 118, no. 2 (July 14, 2011): 368–79. https://doi.org/10.1182/blood-2010-12-326058.Full Text Link to Item
-
Rossi, Davide, Valeria Spina, Clara Deambrogi, Silvia Rasi, Luca Laurenti, Kostas Stamatopoulos, Luca Arcaini, et al. “The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.” Blood 117, no. 12 (March 24, 2011): 3391–3401. https://doi.org/10.1182/blood-2010-09-302174.Full Text Link to Item
-
Kumar, M., Z. Lu, A. A. L. Takwi, W. Chen, N. S. Callander, K. S. Ramos, K. H. Young, and Y. Li. “Negative regulation of the tumor suppressor p53 gene by microRNAs.” Oncogene 30, no. 7 (February 17, 2011): 843–53. https://doi.org/10.1038/onc.2010.457.Full Text Link to Item
-
Rasi, Silvia, Valeria Spina, Alessio Bruscaggin, Tiziana Vaisitti, Claudio Tripodo, Francesco Forconi, Lorenzo De Paoli, et al. “A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.” Br J Haematol 152, no. 3 (February 2011): 284–94. https://doi.org/10.1111/j.1365-2141.2010.08482.x.Full Text Link to Item
-
Visco, Carlo, Sylvia Hoeller, Jeffrey T. Malik, Zijun Y. Xu-Monette, Michele L. Wiggins, Jessica Liu, Warren G. Sanger, et al. “Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.” Am J Surg Pathol 35, no. 2 (February 2011): 177–89. https://doi.org/10.1097/PAS.0b013e3182049a9c.Full Text Open Access Copy Link to Item
-
Lu, Zhongxin, Yan Li, Apana Takwi, Benhui Li, Jingwen Zhang, Daniel J. Conklin, Ken H. Young, Robert Martin, and Yong Li. “miR-301a as an NF-κB activator in pancreatic cancer cells.” Embo J 30, no. 1 (January 5, 2011): 57–67. https://doi.org/10.1038/emboj.2010.296.Full Text Link to Item
-
Ma, Shi-Dong, Subramanya Hegde, Ken H. Young, Ruth Sullivan, Deepika Rajesh, Ying Zhou, Ewa Jankowska-Gan, et al. “A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.” J Virol 85, no. 1 (January 2011): 165–77. https://doi.org/10.1128/JVI.01512-10.Full Text Link to Item
-
Yang, David T., Philip J. Quann, Adam M. Petrich, Catherine P. Leith, Ken H. Young, and Brad S. Kahl. “Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma.” Appl Immunohistochem Mol Morphol 19, no. 1 (January 2011): 62–69. https://doi.org/10.1097/PAI.0b013e3181ed47bc.Full Text Link to Item
-
Wang, Jinyong, Yangang Liu, Zeyang Li, Juan Du, Myung-Jeom Ryu, Philip R. Taylor, Mark D. Fleming, Ken H. Young, Henry Pitot, and Jing Zhang. “Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.” Blood 116, no. 26 (December 23, 2010): 5991–6002. https://doi.org/10.1182/blood-2010-04-281527.Full Text Link to Item
-
Scandurra, Marta, Michael Mian, Timothy C. Greiner, Paola M. V. Rancoita, Cassio P. De Campos, Wing C. Chan, Julie M. Vose, et al. “Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.” Br J Haematol 151, no. 3 (November 2010): 221–31. https://doi.org/10.1111/j.1365-2141.2010.08326.x.Full Text Link to Item
-
Huang, Wan-Ting, Xiaorong Yang, Xiaobo Zhou, Federico A. Monzon, Jianguo Wen, Jill M. Hagenkord, Ling-Yun Wu, et al. “Multiple distinct clones may co-exist in different lineages in myelodysplastic syndromes.” Leuk Res 33, no. 6 (June 2009): 847–53. https://doi.org/10.1016/j.leukres.2008.10.008.Full Text Link to Item
-
Chang, Hong, Connie Qi, Young Trieu, Allan Jiang, Ken H. Young, Alden Chesney, Prashant Jani, Chen Wang, Donna Reece, and Christine Chen. “Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.” Clin Lymphoma Myeloma 9, no. 1 (March 2009): 36–38. https://doi.org/10.3816/CLM.2009.n.008.Full Text Link to Item
-
Zhang, Jing, Jing Wang, Yangang Liu, Harwin Sidik, Ken H. Young, Harvey F. Lodish, and Mark D. Fleming. “Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.” Blood 113, no. 6 (February 5, 2009): 1304–14. https://doi.org/10.1182/blood-2008-01-134262.Full Text Link to Item
-
Amore, Francesco d’, Eric Chan, Javeed Iqbal, Huimin Geng, Ken Young, Li Xiao, Michelle M. Hess, et al. “Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution.” Clin Cancer Res 14, no. 22 (November 15, 2008): 7180–87. https://doi.org/10.1158/1078-0432.CCR-08-0752.Full Text Link to Item
-
Wozniak, Ryan J., Sunduz Keles, Jesse J. Lugus, Ken H. Young, Meghan E. Boyer, Tuan M. Tran, Kyunghee Choi, and Emery H. Bresnick. “Molecular hallmarks of endogenous chromatin complexes containing master regulators of hematopoiesis.” Mol Cell Biol 28, no. 21 (November 2008): 6681–94. https://doi.org/10.1128/MCB.01061-08.Full Text Link to Item
-
Young, Ken H., Karen Leroy, Michael B. Møller, Gisele W. B. Colleoni, Margarita Sánchez-Beato, Fábio R. Kerbauy, Corinne Haioun, et al. “Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.” Blood 112, no. 8 (October 15, 2008): 3088–98. https://doi.org/10.1182/blood-2008-01-129783.Full Text Link to Item
-
Jones, Richard J., Qing Chen, Peter M. Voorhees, Ken H. Young, Nathalie Bruey-Sedano, Dajun Yang, and Robert Z. Orlowski. “Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.” Clin Cancer Res 14, no. 17 (September 1, 2008): 5416–25. https://doi.org/10.1158/1078-0432.CCR-08-0150.Full Text Link to Item
-
Yang, David T., Ken H. Young, Brad S. Kahl, Stephanie Markovina, and Shigeki Miyamoto. “Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.” Mol Cancer 7 (May 19, 2008): 40. https://doi.org/10.1186/1476-4598-7-40.Full Text Link to Item
-
Young, Ken H., Qingmei Xie, Guimei Zhou, Jens C. Eickhoff, Warren G. Sanger, Patricia Aoun, and Wing C. Chan. “Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event.” Am J Clin Pathol 129, no. 1 (January 2008): 157–66. https://doi.org/10.1309/NKK3FEX2BE5L7EKB.Full Text Link to Item
-
Young, Ken H., Dennis D. Weisenburger, Bhavana J. Dave, Lynette Smith, Warren Sanger, Javeed Iqbal, Elias Campo, et al. “Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.” Blood 110, no. 13 (December 15, 2007): 4396–4405. https://doi.org/10.1182/blood-2007-02-072082.Full Text Link to Item
-
Zhao, X Frank, Ken H. Young, Dale Frank, Ami Goradia, Michael P. Glotzbecker, Wilbur Pan, Leslie S. Kersun, Ann Leahey, John P. Dormans, and John K. Choi. “Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.” Am J Clin Pathol 127, no. 1 (January 2007): 47–54. https://doi.org/10.1309/LRQVTE5NM8B9ANLY.Full Text Link to Item
-
Young, Ken H., Wing C. Chan, Kai Fu, Javeed Iqbal, Warren G. Sanger, Anne Ratashak, Timothy C. Greiner, and Dennis D. Weisenburger. “Mantle cell lymphoma with plasma cell differentiation.” Am J Surg Pathol 30, no. 8 (August 2006): 954–61. https://doi.org/10.1097/00000478-200608000-00004.Full Text Link to Item
-
Pirruccello, Samuel J., Ken H. Young, and Patricia Aoun. “Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common.” Am J Clin Pathol 125, no. 6 (June 2006): 884–94. https://doi.org/10.1309/j3et7rxd1x4bkdlf.Full Text Link to Item
-
Rezaie, A. R., and X. He. “Sodium binding site of factor Xa: role of sodium in the prothrombinase complex.” Biochemistry 39, no. 7 (February 22, 2000): 1817–25. https://doi.org/10.1021/bi992006a.Full Text Link to Item
-
He, X., and A. R. Rezaie. “Identification and characterization of the sodium-binding site of activated protein C.” J Biol Chem 274, no. 8 (February 19, 1999): 4970–76. https://doi.org/10.1074/jbc.274.8.4970.Full Text Link to Item
-
He, X., L. Shen, B. O. Villoutreix, and B. Dahlbäck. “Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function.” J Biol Chem 273, no. 42 (October 16, 1998): 27449–58. https://doi.org/10.1074/jbc.273.42.27449.Full Text Link to Item
-
Rezaie, A. R., X. He, and C. T. Esmon. “Thrombomodulin increases the rate of thrombin inhibition by BPTI.” Biochemistry 37, no. 2 (January 13, 1998): 693–99. https://doi.org/10.1021/bi971271y.Full Text Link to Item
-
Borgström, A., X. He, and J. Axelson. “Stimulation with cholecystokinin leads to increased ratio between mRNA levels for anionic and cationic trypsinogen in rat pancreas.” J Gastroenterol 32, no. 6 (December 1997): 797–800. https://doi.org/10.1007/BF02936957.Full Text Link to Item
-
Shen, L., X. He, and B. Dahlbäck. “Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system.” Thromb Haemost 78, no. 3 (September 1997): 1030–36.Link to Item
-
He, X., J. Ye, C. T. Esmon, and A. R. Rezaie. “Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity.” Biochemistry 36, no. 29 (July 22, 1997): 8969–76. https://doi.org/10.1021/bi9704717.Full Text Link to Item
-
Nyberg, P., X. He, Y. Härdig, B. Dahlback, and P. García de Frutos. “Stimulation of Sky tyrosine phosphorylation by bovine protein S--domains involved in the receptor-ligand interaction.” Eur J Biochem 246, no. 1 (May 15, 1997): 147–54. https://doi.org/10.1111/j.1432-1033.1997.t01-2-00147.x.Full Text Link to Item
-
He, X., L. Shen, A. C. Malmborg, K. J. Smith, B. Dahlback, and S. Linse. “Binding site for C4b-binding protein in vitamin K-dependent protein S fully contained in carboxy-terminal laminin-G-type repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance.” Biochemistry 36, no. 12 (March 25, 1997): 3745–54. https://doi.org/10.1021/bi962315q.Full Text Link to Item
-
Fukudome, K., S. Kurosawa, D. J. Stearns-Kurosawa, X. He, A. R. Rezaie, and C. T. Esmon. “The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor.” J Biol Chem 271, no. 29 (July 19, 1996): 17491–98. https://doi.org/10.1074/jbc.271.29.17491.Full Text Link to Item
-
He, X., L. Shen, A. Bjartell, J. Malm, H. Lilja, and B. Dahlbäck. “The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues.” J Histochem Cytochem 43, no. 6 (June 1995): 563–70. https://doi.org/10.1177/43.6.7769227.Full Text Link to Item
-
Zöller, B., X. He, and B. Dahlbäck. “Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.” Thromb Haemost 73, no. 5 (May 1995): 743–45.Link to Item
-
He, X., L. Shen, and B. Dahlbäck. “Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity.” Eur J Biochem 227, no. 1–2 (January 15, 1995): 433–40. https://doi.org/10.1111/j.1432-1033.1995.tb20406.x.Full Text Link to Item
-
He, X., L. Shen, A. Bjartell, and B. Dahlbäck. “The gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by northern blotting, in situ hybridization, and immunohistochemistry.” J Histochem Cytochem 43, no. 1 (January 1995): 85–96. https://doi.org/10.1177/43.1.7822769.Full Text Link to Item
-
Zöller, B., P. J. Svensson, X. He, and B. Dahlbäck. “Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.” J Clin Invest 94, no. 6 (December 1994): 2521–24. https://doi.org/10.1172/JCI117623.Full Text Link to Item
-
Malm, J., X. H. He, A. Bjartell, L. Shen, P. A. Abrahamsson, and B. Dahlbäck. “Vitamin K-dependent protein S in Leydig cells of human testis.” Biochem J 302 ( Pt 3), no. Pt 3 (September 15, 1994): 845–50. https://doi.org/10.1042/bj3020845.Full Text Link to Item
-
He, X., and B. Dahlbäck. “Rabbit plasma, unlike its human counterpart, contains no complex between protein S and C4b-binding protein.” Thromb Haemost 71, no. 4 (April 1994): 446–51.Link to Item
-
He, X., and B. Dahlbäck. “Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S.” Eur J Biochem 217, no. 3 (November 1, 1993): 857–65. https://doi.org/10.1111/j.1432-1033.1993.tb18314.x.Full Text Link to Item
-
-
Book Sections
-
Liu, M. F., S. Jiang, Z. Lu, Y. Li, and K. H. Young. “Physiological and Pathological Functions of Mammalian MicroRNAs.” In Comprehensive Toxicology: Second Edition, 2–14:427–46, 2010. https://doi.org/10.1016/B978-0-08-046884-6.00223-2.Full Text
-
-
Conference Papers
-
Albitar, Maher, Hong Zhang, Andre H. Goy, Zijun Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, et al. “Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms.” In Blood, 138:2395–2395. American Society of Hematology, 2021. https://doi.org/10.1182/blood-2021-148841.Full Text
-
Guo, Wei, Xiaomeng Feng, Yinping Wang, Jia Li, Yangzhi Zhao, Limei Qu, Xu Yan, et al. “The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone Acetate in Peripheral T Cell Lymphomas: A Real-World, Retrospective Case Series from China.” In Blood, 138:4563–4563. American Society of Hematology, 2021. https://doi.org/10.1182/blood-2021-147695.Full Text
-
Guo, Wei, Yangzhi Zhao, Xingtong Wang, Jia Li, Qiang Guo, Junna Li, Ken H. Young, and Ou Bai. “Chidamide Maintenance Therapy after Induction or Salvage Treatment in Patients with Peripheral T-Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation.” In Blood, 138:2442–2442. American Society of Hematology, 2021. https://doi.org/10.1182/blood-2021-152164.Full Text
-
Albitar, Maher, Zijun Yidan Xu-Monette, Babak Shahbaba, Ivan De Dios, Yingjun Wang, Deng Manman, Alexandar Tzankov, et al. “Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning.” In Blood, 134:2891–2891. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126927.Full Text
-
Albitar, Maher, Zijun Yidan Xu-Monette, Wanlong Ma, Yingjun Wang, Deng Manman, Alexandar Tzankov, Carlo Visco, et al. “Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma.” In Blood, 134:1499–1499. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-128516.Full Text
-
Dybkær, Karen, Hanne Due, Rasmus Froberg Brøndum, Ken H. Young, and Martin Bøgsted. “Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP.” In Blood, 134:1623–1623. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-122351.Full Text
-
Wang, Yingjun, Ken H. Young, Denái R. Milton, Celina Ledesma, Elias Jabbour, Zijun Yidan Xu-Monette, Jeffrey J. Molldrem, et al. “Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation.” In Blood, 134:2021–2021. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126719.Full Text
-
Barakat, Mohamad, Maher Albitar, Zijun Xu-Monette, Ken H. Young, and Haifaa Abdulhaq. “Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.” In Journal of Clinical Oncology, Vol. 37, 2019.Link to Item
-
Rassidakis, George, Yi Miao, Jun Zhang, Vassilis Atsaves, Lorand Kis, Karin E. Smedby, Yong Li, Zijun Yidan Xu-Monette, and Ken H. Young. “PD-L1 Expression and Gene Amplification in CD30+Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.Link to Item
-
Xu-Monette, Zijun Yidan, Li Yu, Tran Thai, Lisa Adams, Nathan Roscoe, Ganiraju Manyam, Carlo Visco, et al. “Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.Link to Item
-
Xu-Monette, Zijun Y., and Ken H. Young. “Abstract 666: CD37 tetraspanin as a novel biomarker for PD-1 blockade in diffuse large B-cell lymphoma.” In Cancer Research, 77:666–666. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.am2017-666.Full Text
-
Merrill, E Dean, Rose Agbay, Roberto N. Miranda, Phyu P. Aung, Michael T. Tetzlaff, Ken H. Young, Jonathan L. Curry, et al. “Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas.” In Am J Surg Pathol, 41:204–15, 2017. https://doi.org/10.1097/PAS.0000000000000768.Full Text Link to Item
-
Reinholz, Monica Madden, Debrah Thompson, Ihab Botros, Paul Sportmann, Qian Liu, Pat Roche, Zijun Xu-Monette, Ken H. Young, and Bonnie LaFleur. “Next generation sequencing for DLBCL classification.” In Journal of Clinical Oncology, 34:11559–11559. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11559.Full Text
-
Khouri, Issa F., Rima M. Saliba, Zijun Y. Xu-Monette, Gabriela Rondon, Rosamar Valverde, Martin Korbling, Alison M. Gulbis, et al. “Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT).” In Blood, 122:3350–3350. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.3350.3350.Full Text
-
Ok, Chi Young, Zijun Y. Xu-Monette, Alexander Tzankov, Carlo Visco, Santiago M. Montes, Karen Dybkaer, April Chiu, et al. “STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report Fro The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.Link to Item
-
Xu-Monette, Zijun Y., Alexander Tzankov, Yong Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, et al. “MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.Link to Item
-
Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Alexander Tzankov, Carlo Visco, Roberto N. Miranda, Karen Dybkaer, April Chiu, et al. “Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, 122:213–213. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.213.213.Full Text
-
Zhou, Y., R. Kanagal-Shamanna, S. Hoeller, A. Tzankov, D. Hoehn, S. H. Swerdlow, A. Rosenwald, et al. “Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” In Laboratory Investigation, 92:385A-385A. NATURE PUBLISHING GROUP, 2012.Link to Item
-
Zhou, Y., R. Kanagal-Shamanna, S. Hoeller, A. Tzankov, D. Hoehn, S. H. Swerdlow, A. Rosenwald, et al. “Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” In Modern Pathology, 25:385A-385A. NATURE PUBLISHING GROUP, 2012.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.